Anti-PD-1 Antibodies / PD-1 Inhibitors & Melanoma (cutaneous)

Importance

For cutaneous melanoma, the key Anti-PD-1 Antibodies / PD-1 Inhibitors are nivolumab and pembrolizumab, and they are established standard therapies particularly for unresectable, metastatic, and certain high-risk resected settings.
Lee et al. 2016 Immunotherapy 8(6): 733-46
Sahni et al. 2018 Cureus 10(12): e3700
Trinh et al. 2018 Discov Med 25(135): 31-40

Also, they are standard adjuvant therapy for high-risk resected stage III or IV Melanoma (cutaneous), and neoadjuvant therapy for stage III melanoma i…